Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community
Crossref DOI link: https://doi.org/10.1007/s40259-017-0218-5
Published Online: 2017-04-24
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Markus, Richard
Liu, Jennifer
Ramchandani, Monica
Landa, Diana
Born, Teresa
Kaur, Primal
Funding for this research was provided by:
Amgen
License valid from 2017-04-24